Reviewing ClearPoint Neuro (NASDAQ:CLPT) & Profusa (NASDAQ:PFSA)

ClearPoint Neuro (NASDAQ:CLPT) and Profusa (NASDAQ:PFSA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.

Risk & Volatility

ClearPoint Neuro has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Profusa has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Insider and Institutional Ownership

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 9.8% of Profusa shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 15.0% of Profusa shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares ClearPoint Neuro and Profusa”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$42.28 million	7.62	-$25.54 million	($1.18)	-8.95
Profusa	$100,000.00	4.67	-$35.82 million	($5,619.96)	-0.00

ClearPoint Neuro has higher revenue and earnings than Profusa. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ClearPoint Neuro and Profusa’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
Profusa	N/A	N/A	-1,731.09%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ClearPoint Neuro and Profusa, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1	0	2	0	2.33
Profusa	1	0	0	0	1.00

ClearPoint Neuro presently has a consensus target price of $25.67, suggesting a potential upside of 143.06%. Given ClearPoint Neuro’s stronger consensus rating and higher possible upside, analysts plainly believe ClearPoint Neuro is more favorable than Profusa.

Summary

ClearPoint Neuro beats Profusa on 10 of the 14 factors compared between the two stocks.

About ClearPoint Neuro

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.